New versus Old Oral Anticoagulants: How Can We Set the Scale Needle? Considerations on a Case Report
Francesca Antonia Arcadi1, Simona Portaro2, Roberto Giorgianni3
1IRCCS Centro Neurolesi "Bonino-Pulejo", 98123 Messina, Italy. francesca.arcadi@irccsme.it.
Abstract:
Ischemic stroke is a complex multifactorial disorder. Anticoagulation is a growing research area, with the main goal of preventing systemic embolization and stroke. We report the case of a 41-year-old woman with antiphospholipid syndrome who was unsuccessfully treated with Dabigatran, a new oral anticoagulant, as she developed a major stroke involving the right carotid artery, due to deep venous thrombosis with pulmonary embolism. We therefore suggest a closer monitoring of the safety and efficacy of dabigatran. Moreover, in the presence of multifactorial causes of pro-coagulation, we believe that warfarin should remain the mainstay of oral anticoagulation.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Data Reporting and Recording
Design Consideration
The factor of safety is another key...
pH Scale
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Tensile Strength Considerations of Concrete
The dimensions and shape of a concrete specimen...


